ASAM 47th Annual Conference - Innovations in Addiction Medicine and Science - 2016 (69 CME)

The ASAM Annual Conference is the nation's premiere event providing the latest innovations and scientific developments in addiction medicine. The program includes exciting changes in format and structure to provide learning in a more interactive, casual and fun environment.

Meeting highlights include; symposia, workshops, poster presentations, special focus sessions and fun events designed to allow more effective learning and networking. Participate in the front-running conference that specializes in addiction medicine:

  • Learn about new tools for diagnosis, treatment, patient care and public policy
  • Explore the newest research and developments shaping the future of addiction medicine
  • Network with medical professionals, researchers, leading scientists and policy advocates
  • Find out about the latest science from leaders of federal agencies and institutions
  • Discover evidence-based techniques, tools, technologies and practices
  • Engage in discussions about strategies of integration of addiction medicine and primary care
  • Participate in special on and off-site sessions that dive into substance use in Baltimore and the programs that seek to address it.

 

  • Evaluation and Certificate - 47th Annual Conference

    Contains 3 Component(s), Medical Credits Offered

    CME Evaluation for the ASAM Annual Conference.

    Download the CME Tracking Sheet to assist with recording sessions attended at the conference. Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Payment for Addiction Medicine Services- ASAM Advocacy in Action (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    This session will provide an overview of the health care financing system in the United States as related to health plan coverage of addiction medicine services, as well as describe more efficient and effective ways to manage the prior authorization process in your practice. Learn how insurers make coverage decisions, what types of payment models exist, and what that insurance card in your wallet really means.

    Are you tired of spending hours filling out prior authorization forms only to be denied coverage? Are you puzzled as to why people can pay premiums but not have addiction services covered, even after “parity"? Do you wonder what that insurance card in your wallet really means? ASAM has a newly developed Payer Relations Committee to address a multitude of payment issues. In order to advocate for our profession, our practices, and our patients to access payments for addiction treatment services, we must start by understanding the system in place. This workshop will begin by providing an overview of the health care financing system in the United States as related to health plan coverage of addiction medicine services, how insurers make coverage decisions, and what types of payment models exist. We'll discuss efficient and effective ways for addiction physicians to handle the prior authorization and other processes with payers - what does and does not work to get coverage approvals. And we will discuss the mission of the new Payer Relations Committee and the many areas for improvement you can help identify.

    H. Westley Clark

    MD, JD, MPH, CAS, FASAM

    Dr. H. Westley Clark, Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, leads the agency's national effort to provide effective and accessible treatment to all Americans with addictive disorders. Dr. Clark was the former chief of the Associated Substance Abuse Programs at the U.S. Department of Veterans Affairs Medical Center (DVAMC) in San Francisco, California and a former associate clinical professor, Department of Psychiatry, University of California at San Francisco (UCSF). In addition to his duties at the DVAMC, Dr. Clark served as a senior program consultant to the Robert Wood Johnson, Substance Abuse Policy Program, a co-investigator on a number of the National Institute on Drug Abuse-funded research grants in conjunction with UCSF.

    Dr. Clark is a noted author and educator in substance abuse treatment, anger and pain management, psychopharmacology, and medical and legal issues. He has received numerous awards for his contributions to the field of substance abuse treatment, including a 2008 President of the United States Rank of Distinguished Executive Award in recognition of his personal commitment to excellence in government and public service; and a 2003 President of the United States of America Rank of Meritorious Executive Award in the Senior Executive Service for his sustained superior accomplishments in management of programs of the United States Government and for noteworthy achievement of quality and efficiency in the public service, 2003. In addition, he was awarded the 2008 John P. McGovern Award from the American Society of Addiction Medicine for his contributions toward increased understanding of the relationship between addiction and society.

    Other awards include the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service far exceeding Departmental standards of achievement by exhibiting outstanding teamwork and timeliness on the complex task of completing the Methadone Final Rule which required coordination among several Federal agencies, 2001; Vernelle Fox Award from the California Society of Addiction Medicine for excellence in Addiction Medicine, Education and Public Service, 2000.

    Dr. Clark received a B.A. in Chemistry from Wayne State University in Detroit, Michigan; he holds a Medical Degree and a Masters in Public Health from the University of Michigan, Ann Arbor; where he completed a Psychiatric Residency at University Hospital, Neuropsychiatric Institute. He obtained his Juris Doctorate from Harvard University Law School and completed a two-year Substance Abuse Fellowship at the DVAMC-SF. Dr. Clark received his board certification from the American Board of Psychiatry and Neurology in Psychiatry and sub-specialty certification in Addiction Psychiatry. Dr. Clark is licensed to practice medicine in California, Maryland, Massachusetts and Michigan. He is also a member of the Washington, D.C., Bar Association.

    Kelly Clark

    MD, MBA, DFASAM, DFAPA

    Dr. Kelly J. Clark is the President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

    Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

    As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

    As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

  • A New World: Update on Recognizing ADM as an ABMS Subspecialty (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1™ credits while learning about a brief chronology of the origins and current status of the field of addiction medicine. The speakers will also provide an update on the recognition process underway at the time of this presentation. The process of recognition of a new medical field by the American Board of Medical Specialties will be reviewed, with attention to the impact of recognition on existing diplomates and future examination applicants.

    In 1954 Dr. Ruth Fox in New York City set the foundation for the present field of addiction medicine (ADM) when she established the organization now known as the American Society Addiction Medicine (ASAM). ASAM began pursuing recognition for addiction medicine within organized medicine in 1991. In 2007 the American Board of Addiction Medicine (ABAM) was established with the encouragement and facilitation of ASAM, and ABAM then began addressing and fulfilling the recognition requirements by the American Board of Medical Specialties (ABMS)for recognition of the field. By mid-2015 these requirements, which included the establishment of a sufficient number of ADM fellowships, had been fulfilled. ABAM held multiple meetings with ABMS and its member boards. ABPM submitted an application to ABMS for recognition of ADM in May, 2015. A brief history of ABMS, its mission, function and processes, as well as information about its member boards will be reviewed. The history, structure and function of ABPM will be reviewed, with attention to the format and expectations for the new subspecialty. At the time this abstract was submitted, the application from ABPM to ABMS was still under consideration. It is expected that addiction medicine will be a multi-specialty subspecialty open to any physician holding an ABMS primary certificate. There is typically a five-year practice pathway for physician certification in a new field before an ACGME accredited ADM fellowship is required. In this session, ABAM representatives will bring the audience up to date on this process and its outcome. Also covered will be the multiple impacts of formal recognition by ABMS. These include new accommodations expected by health care systems and third party insurers; changes in the education and training environments of all physicians; accreditation of ADM fellowships by the Accreditation Council for Graduate Medical education; the status and future of current ASAM and ABAM certificates; expected eligibility requirements for future ADM certification examinations; anticipated requirements for an ADM MOC program; and a brief history of ACGME, its mission, functions and processes will be reviewed. the importance of ASAM as the leadership organization for physicians practicing addiction medicine. The addiction medicine subspecialty will need a pipeline for fellowship trained physicians, and the ACGME requirements for fellowship accreditation and the plan to establish additional ADM fellowships will be presented. The current fellowships accredited by The ABAM Foundation will be reviewed, with attention to their faculty, fellows and curriculum. The purposed and activities of the ADM Fellowship Director's group will be presented. The session will conclude with a question and answer section.

    Robert Sokol

    MD

    Dr. Robert J. Sokol currently serves as a Distinguished Professor of Obstetrics and Gynecology and Physiology and the John M. Malone, Jr., M.D., Endowed Chair and Director of the C.S. Mott Center for Human Growth and Development at Wayne State University in Detroit, Mich. Dr. Sokol graduated with the highest distinction in philosophy and from medical school with honors from the University of Rochester in New York. After residency training at Washington University/Barnes Hospital in St. Louis, Mo., and after serving as Dr. Willard Allen's last executive Chief Resident, he served in the Air Force as a Major and then completed a fellowship at Maternal-Fetal Medicine, as well as joining the faculty, first at the University of Rochester and then at Metrohealth/Case Western Reserve in Cleveland. He worked his way up to Professor and Director of the Perinatal Clinical Research Center. Recruited as Chair of the Department of Obstetrics and Gynecology at the Wayne State University School of Medicine/Detroit Medical Center in 1983, he served as Dean and Senior Vice President for Medical Affairs from 1988 until 1999. Dr. Sokol is an internationally recognized expert in the area of fetal alcohol spectrum disorders. In 1986, he established and directed the National Institutes of Health-funded WSU Fetal Alcohol Research Center, the only center of its kind in the country at the time. He is currently focused on risk detection and prevention methodology. He is Project Manager II for services in support of the Perinatology Research Branch of the NICHD and was the founding Chair of a University Department of Clinical and Translational Science. He has about 335 referreed papers and about 1500 total publications. He is President Elect of the American Board of Addiction Medicine.

    Patrick O'Connor

    MD, MPH, FACP

    No Biography

    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Kevin Kunz

    MD, MPH, DFASAM

    Kevin Kunz, M.D., M.P.H., DFASAM is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation. He served as ABAM President from 2008-2011, and previously served as an ASAM Director and Chair of the ASAM Chapters Council. He was Co-chair of the ASAM Medical Specialty Action Group, which recommended that an independent medical board be established to expand the formal involvement of the larger medical community and all of health care in the prevention and treatment of addiction.

    William Greaves

    MD. MSPH

    Executive Director, ABPM

  • Developing Fellowship Training Programs to Meet Workforce Needs (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 credit while learning how specialized physician training is the sine qua non of every medical specialty and sub-specialty. Considerable opportunity exists for academic and community physicians who are interested in taking a place in addiction medicine’s future leadership by building new fellowship training programs.

    Specialized physician training is the sine qua non of every medical specialty and sub-specialty. Addiction Medicine is entering a new phase as its fellowship training programs, which have played a central role in the discipline's steady progression toward recognition, assume increasing responsibility for meeting the nation's addiction workforce needs. The more than three dozen fellowships that have been accredited so far by The Addiction Medicine Foundation have laid the groundwork for a national training infrastructure. These programs represent only the first wave toward achieving a target training capacity that is estimated to be in the range of 200-300 fellowship graduates per year. Considerable opportunity exists, therefore, for academic and community physicians who are interested in taking a place in addiction medicine's future leadership by building new fellowships. This interactive workshop will equip participants with a step-by-step road map for fellowship development, including identifying key team members, cultivating relationships with institutional partners, and designing clinical and didactic curricula. The requirements for fellowship accreditation will be explained, and particular attention will be devoted to the policies of the Accreditation Council for Graduate Medical Education (ACGME). Concrete examples will be provided from operating fellowships so participants will have a better understanding of key issues such as rotation design and budgeting. The importance of incorporating prevention and early intervention into training will be explained, and Addiction Medicine Foundation representatives will also offer updates on recent developments that have implications for areas such as fellowship funding. The workshop, therefore, will be of value to administrators and other health professionals, as well as physicians. Questions and open discussion will be encouraged throughout, and participants who wish will be linked with the Addiction Medicine Foundation's National Center for Physician Training in Addiction Medicine for ongoing technical assistance with fellowship development.

    Richard Blondell

    MD, MPH, FASAM

    Richard Blondell graduated from the University of Rochester school of medicine In 1978, and completed a family medicine residency at the University of Louisville in 1981. Following some time in private practice, he returned to the University of Louisville in 1985 and served as the director of the residency program from 1989 until 1997. After a sabbatical, he completed the certification requirements of the American Society of Addiction Medicine in 1998. Subsequently, he developed and directed a consult service on addiction medicine at the University of Louisville Hospital from 1998 to 2003. In 2003 he moved the University of Buffalo to pursue research interests in addiction medicine. He has served as a member of the Board of Directors of the American Board of Addiction medicine since 2007 and coordinates the Addiction Medicine Fellowship accreditation activities for ABAM-Foundation. No disclosures

    Kevin Kunz

    MD, MPH, DFASAM

    Kevin Kunz, M.D., M.P.H., DFASAM is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation. He served as ABAM President from 2008-2011, and previously served as an ASAM Director and Chair of the ASAM Chapters Council. He was Co-chair of the ASAM Medical Specialty Action Group, which recommended that an independent medical board be established to expand the formal involvement of the larger medical community and all of health care in the prevention and treatment of addiction.

    Randall Brown

    MD, PhD, DFASAM

    Dr. Brown is on the Board of Directors of The Addiction Medicine Foundation and is President-Elect of the Addiction Medicine Fellowship Directors Association. He is Board Certified in Family Medicine and Addiction Medicine. He has been heavily involved in fellowship development at the program for which he was the founding Director at the University of Wisconsin School of Medicine and Public Health, as well as at the national level. He serves as a consulting physician in addiction medicine at UW Hospital (where he is the Director of the Center for Addictive Disorders), William S. Middleton Memorial Veterans Hospital, the UW Hospital HIV/AIDS Clinic, and at Access Community Health Centers (a network of Federally Qualified Health Centers). Dr. Brown is also the Director of the UW SMPH fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin. Dr. Brown holds a PhD in Population Health Sciences from the University of Wisconsin.

    Andrew Danzo

    BA

    Mr. Danzo is Coordinator of the ABAM Foundation National Center for Physician Training in Addiction Medicine. He is also Associate Director of Program Development in the University at Buffalo Primary Care Research Institute and research instructor in the University at Buffalo Department of Family Medicine.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    The ASAM 47th Annual Conference begins with the exciting Opening Scientific Plenary. Led by ASAM President R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM, the Opening Scientific Plenary features an exciting lineup of ASAM award winners and leaders in the addiction medicine field: Nora Volkow, MD; William Miller, PhD; Governor Peter Shumlin (D-VT)

    The ASAM 47th Annual Conference begins with the exciting Opening Scientific Plenary. Led by ASAM President R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM, the Opening Scientific Plenary features an exciting lineup of ASAM award winners and leaders in the addiction medicine field.

    Nora Volkow, MD Director, National Institute on Drug Abuse, Special Guest 

    The Opioid Crisis: What Can We Do To Curtail It? — Opioid use and its often tragic consequences have dramatically increased in recent years. This presentation will highlight ongoing efforts to help fill this treatment gap and to curtail this serious opioid epidemic in a number of ways. 

    Note: Please see the handouts tab for Dr. Volkow's updated slides and comments.

    William Miller, PhD R. Brinkley Smithers Distinguished Scientist Award Winner

    The Power of Empathy in Addiction Treatment — Whatever the content of treatment, therapeutic relationship continues to be a strong predictor of patient outcomes. Drawing on a range of clinical research across four decades, Dr. Miller will describe the therapeutic quality of accurate empathy as an important, learnable, and evidence-based component of effective treatment.

    Governor Peter ShumlinGovernor of Vermont, Special Guest

    Confronting America's Addiction to Opioids: A State Prescription for Identifying and Addressing the Crisis — In 2014, Vermont Governor Peter Shumlin devoted his State of the State proposal to battle opioid and heroin addiction. Since then, his state has expanded drug treatment and pre-trial risk-assessment programs to provide Vermonters with help to beat their addiction while combating a statewide epidemic.

    Nora Volkow, MD

    Director, National Institute on Drug Abuse, National Institutes of Health

    Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. Her work has been instrumental in demonstrating that drug addiction is a disease of the human brain. She pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs and has also made important contributions to the neurobiology of obesity, ADHD, and aging.

    Dr. Volkow was born in Mexico, earned her medical degree from the National University of Mexico, and carried out her psychiatric residency at New York University. Prior to her tenure at NIDA she held leadership positions at the Department of Energy's Brookhaven National Laboratory including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. She was also a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.

    Dr. Volkow has published more than 600 scientific articles and edited three books on neuroimaging for mental and addictive disorders. Among her many awards have been selection for membership in the Institute of Medicine, and the International Prize from the French Institute of Health and Medical Research. She was also named one of Time Magazine's “Top 100 People Who Shape our World", included as “One of the 20 People to Watch" by Newsweek magazine, and named “Innovator of the year" by U.S. News & World Report in 2000.

    William Miller, PhD

    Emeritus Distinguished Professor of Psychology and Psychiatry, University of New Mexico

    Dr. William R. Miller is Emeritus Distinguished Professor of Psychology and Psychiatry at the University of New Mexico where he served as Director of Clinical Training for the doctoral program in clinical psychology and as Co-Director of the Center on Alcoholism, Substance Abuse and Addictions (CASAA). Dr. Miller's publications include over 50 books and 400 articles and chapters including the original 1983 description of the clinical method of motivational interviewing. Fundamentally interested in the psychology of change, he has focused in particular on the development, testing, and dissemination of behavioral treatments for addictions. With more than 40 years of experience in addiction research and treatment, he has served as principal investigator for numerous research grants and contracts, founded a private practice group, directed a large public treatment program, and served as a consultant to many organizations including the United States Senate, the World Health Organization, the National Academy of Sciences, and the National Institutes of Health. In recognition of his research contributions, Dr. Miller is a recipient of the international Jellinek Memorial Award, two career achievement awards from the American Psychological Association, and an Innovators in Combating Substance Abuse award from the Robert Wood Johnson Foundation. He maintains an active interest in the interface of spirituality and psychology. His books have been translated into 26 languages and the Institute for Scientific Information has listed him as one of the world's most cited scientists.

    Governor Peter Shumlin

    Governor of Vermont

    Peter Shumlin is a small business owner, public servant and father of two from Putney, Vermont.

    As Governor, Peter is determined to get tough things done. Since his inauguration, he has been working hard to create jobs for those who need them and raise incomes for those who have jobs, control skyrocketing health care costs, expand broadband and cell service to every corner of the state, reduce recidivism, invest in quality education opportunities, and rebuild our roads and bridges. Taken together, these and other key goals represent an ambitious agenda to create a brighter economic future for Vermonters.

    Peter is the father of two daughters, Olivia and Rebecca. In his free time he enjoys running, hiking and cross country skiing. He likes to fish, hunt and garden and can sometimes be found spreading manure and cutting hay at his farm.

    Peter is the 81st Governor of Vermont.

  • Clinical Guidance for Treating Opioid-Dependent Pregnant and Parenting Women and Their Babies (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 credits while learning how practitioners treating opioid-dependent pregnant and parenting women and their children lack clear recommendations on how to care for this population, and clinical evidence is still limited. The panel will discuss how the recommendations for treating opioid-dependent pregnant and parenting women and their children will be translated into a practical clinical guide.

    Practitioners treating opioid-dependent pregnant and parenting women and their children lack clear recommendations on how to care for this population, and clinical evidence is still limited. The Substance Abuse and Mental Health Services Administration (SAMHSA) convened a national expert panel and implemented the RAND/UCLA Appropriateness Method (RAM) to assess the appropriateness of clinical procedures to treat this population and provide clinical recommendations. Recommendations were derived from a literature review of evidence-based practices (EBPs) and clinical judgment deemed appropriate and applicable for a variety of settings. Using the RAM results, the panel will discuss areas of agreement for the appropriateness of certain procedures to improve the care of opioid-dependent pregnant and parenting women and their children, as well as areas where EBPs are not available and clinical judgment is not agreed on. The panel will discuss how the recommendations for treating opioid-dependent pregnant and parenting women and their children will be translated into a practical clinical guide. Audience members will be invited to provide their perspectives on areas where questions remain on appropriate clinical treatment.

    Hendree Jones, PhD

    Professor of OB/GYN and Executive Director Horizons Program, UNC School of Medicine

    Hendree Jones, PhD is a Professor in the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill and Executive Director of Horizons, a comprehensive drug treatment program for pregnant and parenting women and their drug-exposed children. She is also an Adjunct Professor in the Department of Psychology, UNC, Chapel Hill and an Adjunct Professor in the Psychiatry and Behavioral Sciences and in the Department of Obstetrics and Gynecology, School of Medicine, Johns Hopkins University. Dr. Jones is an internationally recognized expert in the development and examination of both behavioral and pharmacologic treatments for pregnant women and their children in risky life situations. Dr. Jones has received continuous funding from the United States National Institutes of Health since 1994 and has published over 160 publications, two books on treating substance use disorders (one for pregnant and parenting women and the other for a more general population of patients), several book and textbook chapters. She is a consultant for the United Nations and the World Health Organization. Dr. Jones leads or is involved in projects in Afghanistan, the Southern Cone, the Republic of Georgia, South Africa, and the United States which are focused on improving the lives of children, women and families.

    Melinda Campopiano, MD

    Medical Officer, Substance Abuse and Mental Health Services Administration

    Dr. Melinda Campopiano currently serves as Medical Officer for the Center for Substance Abuse Treatment at the Substance Abuse Mental Health Services Administration (SAMHSA). She is a physician Board Certified in Family Medicine with additional credentialing in Addiction Medicine.

    Dr. Campopiano has worked in both primary care and addiction medicine including managing programs and patients using methadone and buprenorphine. Prior to joining SAMHSA, she participated in the development, implementations and evaluation of a curriculum in SBIRT for medical students and residents at the Pennsylvania Department of Health Bureau of Drug and Alcohol Programs.

    Diana Coffa

    MD

    Dr. Coffa is the Residency Program Director for the Family and Community Medicine Residency program at the University of California, San Francisco. in addition to practicing full spectrum primary care, Dr. Coffa co-leads an addiction consultation clinic and directs the chronic pain programs at the Family Health Center, an FQHC teaching clinic. She oversees the clinic's buprenorphine program and ensures that residents in family medicine, internal medicine, pediatrics, obstetrics, and psychiatry have access to buprenorphine training. She is also the primary consultant for buprenorphine prescribing at Zuckerberg San Francisco General Hospital, providing clinical guidance to hospital and maternal care providers who are treating hospitlalized patients for opioid use disorder.

    Mishka Terplan

    MD, MPH, FACOG, FASAM

    Mishka Terplan is a physician boarded in both obstetrics and gynecology and addiction medicine. His clinical, research and advocacy work focuses on the intersection of reproductive health and addictions. He is currently Medical Director of Behavioral Health System Baltimore, the local behavioral health authority, adjunct faculty at University of Maryland Department Epidemiology and Public Health, and staff physician at Planned Parenthood Maryland. He has represented both the American Congress of Obstetricians and Gynecologists (ACOG) and the American Society of Addiction Medicine (ASAM) on federal taskforces and in testimony including before the House Energy and Commerce Subcommittee regarding H.R. 1462, the “Protecting Our Infants Act".

    Stephen Patrick, MD, MPH, MS

    Assistant Professor of Pediatrics and Health Policy, Division of Neonatology / Vanderbilt University

    Stephen W. Patrick, MD, MPH, MS, is an Assistant Professor of Pediatrics and Health Policy at Vanderbilt University School of Medicine and an attending neonatologist at Monroe Carell Jr. Children's Hospital at Vanderbilt. He is a graduate of the University of Florida, Florida State University College of Medicine and Harvard School of Public Health. Dr. Patrick completed his training in pediatrics, neonatology and health services research as a Robert Wood Johnson Foundation Clinical Scholar at the University of Michigan.

    Dr. Patrick joined the faculty of Vanderbilt University in 2013. His research focuses on improving outcomes for opioid-exposed infants and women with substance-use disorder and evaluating state and federal drug control policies. He previously served as Senior Science Policy Advisor to the White House Office of National Drug Control Policy and has testified before Congress on the rising numbers of newborns being diagnosed with opioid withdrawal after birth. He currently serves as an expert consultant for the Substance Abuse and Mental Health Services Administration's development of a Guide to the Management of Opioid-Dependent Pregnant and Parenting Women and Their Children, as a member of the American Academy of Pediatrics Committee on Substance Abuse and as a board member on the US Office of Personnel Management's Multi-State Plan Program Advisory Board. Dr. Patrick's awards include the American Medical Association Foundation Excellence in Medicine Leadership Award and the Academic Pediatric Association Fellow Research Award. His research has been published in leading scientific journals including the New England Journal of Medicine, JAMA, Pediatrics and Health Affairs.

    Susan Hayashi, PhD

    Vice President, JBS International, Inc.

    Dr. Hayashi is Vice President of JBS International, Inc.

    Joseph George Perpich, MD, JD

    Senior Medical Advisor, JBS International, Inc.

    Joseph Perpich, MD, JD, a psychiatrist and attorney, is Senior Medical Advisor at JBS International, Inc (JBS). At JBS, he develops professional products and provides training and technical assistance services related to prevention of prescription drug abuse and overdose and medication assisted treatments for opioid use disorder. Prior to joining JBS, he led at JG Perpich, LLC the development and management of behavioral health research networks with a focus on international drug abuse, suicide prevention, and behavioral health services for the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH.) Dr. Perpich has served as Associate Director for Program Planning and Evaluation at the National Institutes of Health where he directed government-wide activities related to recombinant DNA research and regulatory policies (1976 to 1981). Before founding JGPerpich, LLC in 2002, Dr. Perpich was Vice President for Grants and Special Programs at the Howard Hughes Medical Institute, where he created and managed the grants program for science education and international biomedical research.

    Krystyna R. Isaacs, PhD

    Senior Research Fellow, JBS International, Inc.

    CURRENT EMPLOYMENT

    2012-Present JBS International, Project Director/Sr Research Fellow, North Bethesda, MD – Current responsibilities include researching and preparing articles, briefs, and program reports for clients at NIH and SAMHSA.

    PAST EMPLOYMENT

    2001 – 2012 JGPerpich, LLC, Vice President, Program Development, Bethesda, MD - As Project Manager and then Vice President for NIH Small Business Innovative Research (SBIR) Contracts and Cooperative Agreements at JGP, I was primarily responsible for planning and writing several successful SBIR and Cooperative Agreement proposals; coordination of the Advisory Board activities and meetings; managing deliverables and budget for SBIR contracts; organizing numerous virtual working group sessions to develop scientific content for conferences, leadership meetings, and white papers; writing formal evaluations of pilot activities and preparing summary reports; producing multiple career development webinar series, including ones related to Academic Development Plans, scientific presentations, and publications; and facilitating the development of several working groups to produce a scientific presentation at a national meeting on suicide and special populations; arranging workshops for scientific meetings.

    1997 – 1998 Howard Hughes Medical Institute, International Program, Program Analyst, Chevy Chase, MD - Organized scientific workshops, international meetings and visiting lectureships abroad; prepared press releases for international grantees; managed international scientific grants; initiated development of electronic information access for foreign research scholars.

    1992 – 1997 National Institute of Mental Health, Laboratory of Clinical Science, Postdoctoral Fellow & Senior Staff Fellow, Bethesda, MD; Twenty-eight peer-reviewed publications

    Anne Leopold, MSc

    Project Manager, JBS International, Inc.

    Anne Leopold is a Project Manager at JBS International, Inc.

  • MAT for SUD: Review of Medications, Research Evidence, and Implementation Effort Disparities (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    This three-part Symposium will begin with a review of alcohol and opioid use in the United States and the FDA-approved medications for treating alcohol and opioid use disorders, followed by a discussion of the major findings from two NIDA Clinical Trials Network research studies focused on the use of buprenorphine with young adult heroin users and prescription opioid users. The Symposium will conclude with a discussion of the results from a study that surveyed 192 substance use disorder treatment programs about the availability of medication-assisted treatment (MAT) and racial disparities in access to MAT among American Indian and Alaska Native populations. This portion of the Symposium will include barriers to MAT adoption in treatment programs that serve these communities and recommendations for improving access to MAT for AI/AN populations.

    This Symposium will feature three presentations focused on the use of medications in the treatment of alcohol and opioid use disorders. The first presentation will begin with a discussion of the context for medication-assisted treatment (positive and negative perceptions), the epidemiology of alcohol and opioid use (user demographics), a review of the various classes of opioids, an overview of each FDA-approved medication, its indication, to whom it is administered, and how it works, and treatment settings for medication-assisted treatment (MAT). Medications will include: naltrexone, methadone, acamprosate, and buprenorphine. Part I will conclude with a discussion of strategies that can be utilized with clients to talk about their use of medications, and strategies to address health disparities through increased access to medication-assisted treatment. The second presentation will review the key findings from two NIDA Clinical Trials Network studies that were conducted to assess the use of buprenorphine with young adult heroin dependent individuals and prescription opioid dependent individuals. Key topics will include a review of each protocol, participant demographics, results, and clinical implications. The third presentation will describe the use of MAT of substance use disorders for American Indians and Alaska Natives (AIs/ANs) and barriers to broader implementation of MAT in treatment settings that serve these communities. American Indians and Alaska Natives (AI/ANs) experience higher rates of substance use disorders and less access to high-quality care than other racial/ethnic groups.

    Thomas Freese, PhD

    Principal Investigator and Co-Director, Pacific Southwest Addiction Technology Transfer Center (Pacific Southwest ATTC, HHS Region 9)

    Thomas E. Freese, Ph.D., received his doctorate degree in clinical psychology from the California School of Professional Psychology in 1995. Dr. Freese is currently the Director of Training for UCLA ISAP, Principal Investigator and Director of the SAMHSA-funded Pacific Southwest Addiction Technology Transfer Center (PSATTC, HHS Region 9), and Principal Investigator and Co-Director of the SAMHSA-funded Center of Excellence on Racial and Ethnic Young Men Who Have Sex with Men and Other Lesbian, Gay, Bisexual, and Transgender Individuals (YMSM+LGBT CoE). Dr. Freese has served as Principal Investigator on projects funded by the California Department of Alcohol and Drug Programs and Department of Health Care Services to train providers to implement Screening, Brief Intervention, and Referral to Treatment (SBIRT). Dr. Freese has also led several large projects that assist providers in implementing integrated treatment for co-occurring mental health and substance use disorders. He has been a featured presenter at conferences and meetings nationally and internationally on the impact and treatment of methamphetamine and opioid dependence. In addition, Dr. Freese has served as the Project Director on a number of studies including research on methamphetamine use. He has worked in the addiction field since 1983, and has developed and conducted trainings in 45 states and internationally, providing training and workshops for clinicians-in-training at the all levels.

    Beth Rutkowski, MPH

    Associate Director of Training and Epidemiologist, UCLA Integrated Substance Abuse Programs, Pacific Southwest ATTC

    Beth Rutkowski received her Master of Public Health degree in 2000, with an emphasis on epidemiology and quantitative methods, from the University of Medicine and Dentistry of New Jersey, School of Public Health. She has been associated with UCLA's Integrated Substance Abuse Programs (ISAP) since December 2000, and currently serves as the Associate Director of Training. The majority of Ms. Rutkowski's time is devoted to the SAMHSA-supported Pacific Southwest Addiction Technology Training Center, where she develops training packages based on evidence-based substance use disorder research and targeted to the community at large. In addition, she organizes and conducts conferences and trainings throughout the Pacific Southwest region (HHS Region 9, covering AZ, CA, HI, NV, and the six U.S. Affiliated Pacific Jurisdictions) on scientifically validated interventions and topics, such as substance use disorders research and policy, methamphetamine abuse, synthetic drugs, process improvement strategies to improve client engagement and retention in treatment, SBIRT, HIV and drug abuse, substance abuse epidemiology, medication-assisted treatment, and best practices in addiction treatment.

    Traci Rieckmann, PhD

    Associate Director, Oregon Health and Science University, Northwest ATTC

    Dr. Rieckmann is an Associate Professor in the School of Public Health at Oregon Health & Science University. She leads the Behavioral Health Innovations Team which serves as leaders at the intersection of research, implementaion and training for local and national health services. This draws from her role as Principal Investigator at Northwest Addiction Technology and Transfer Center (NWATTC), and co-investigator on a NIDA R21/R33 examining the impact of Oregon's Medicaid expansion and ACO development on patients with substance use disorders. She pulls from her experience serving as Principal Investigator on federal NIH and SAMHSA awards, a state contract examining implementation of medication assisted treatment (MAT) in a local community health center, and two protocols within the National Institute on Drug Abuse Clinical Trials Network. Her research focuses on the clinical development and successful implementation of behavioral and pharmacological substance use disorder treatment protocols, extensive project management experience with community-based clinical care settings and primary care. My clinical background and expertise in mixed-methodologies contribute to my broad understanding of behavioral health, integrative medicine and the translation of research to practice.

  • Beyond Specialty Care: Healthcare, Justice, MAT and Financial Interventions and Report Cards (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.0 AMA PRA Category 1 Credit(s)™ credits while learning about health reform facilitates going beyond substance use disorder specialty care and integrating it with various other portals (e.g., general healthcare, criminal justice systems) and innovative resources (e.g., MAT, financial interventions) to improve outcomes. Also new is the emergence of report cards for rating quality care. This session will introduce translational research data from random controlled trials and change models in medical centers, drug courts/jails and addiction treatment programs, as well as financial transaction tracking of patient spending behavior in the community.

    BACKGROUND

    Health reform facilitates going beyond substance use disorder specialty care and integrating it with various other portals (e.g., general healthcare, criminal justice systems) and innovative resources (e.g., MAT, financial interventions) to improve outcomes for patients and society. Also new is the emergence of report cards for rating quality care. This session will introduce translational research that implements promising real-world approaches for: 1) interventions in non-specialty addiction care; 2) integration of medical care and addiction treatment and support recovery processes; and 3) treatment program quality ratings to facilitate specialty care selection and improvement. 

    GENERAL HEALTHCARE INTEGRATION

    Dr. Adam Brooks will present results from a RCT in federally qualified health centers examining substance use and treatment engagement outcomes for patients who receive either a 1-session SBIRT or brief treatment. These preliminary data describe the adaptation of this model to medically fragile substance using patients in a safety net hospital. CRIMINAL 

    JUSTICE INTEGRATION

    Dr. David Festinger will discuss the prevalence of drug and alcohol use and HIV in criminal justice populations. He will present an RCT of a computerized HIV-risk reduction intervention for substance-abusing criminal justice clients who were diverted to community-based supervision and treatment. The intervention increased HIV testing and condom acceptance. MEDICATION-ASSISTED 

    TREATMENT

    Dr. Mady Chalk will describe the Advancing Recovery System Change Model, designed to accelerate implementation of MAT and its integration with medical care. This includes the use of acamprosate, disulfiram oral- and extended-release naltrexone for alcohol dependence and buprenorphine and extended-release naltrexone for opioid dependence and their impacts on healthcare utilization. Medication use increased in the intervention sites and was maintained and enhanced during the second year post-intervention. FINANCIAL 

    INTERVENTION

    Largely overlooked is the role of patients' funds in early recovery relapse risk. Dr. David Gastfriend will present preliminary data illustrating the feasibility and usage of the Next Step Debit Card, a tool that has the potential to support the recovery process by allowing monitored access to funds while restricting transaction times, cash withdrawals, and use at establishments associated with high relapse risk (e.g., liquor stores, bars, casinos). 

    CONSUMER GUIDE RATINGS

    Those outside the specialty sector (e.g., families, referrers), lack objective quality data for selecting treatment programs. Meanwhile, programs with limited resources need better data about which quality improvement areas to target. Dr. Kathleen Meyers will describe a systematic methodology used to evaluate the quality of community treatment programs and its translation into a practical and science-based “report-card - The Consumer Guide to Substance Abuse Treatment" that can inform and direct selection of treatment. 

    DISCUSSION

    In the new era of healthcare reform, multiple portals and resources can go beyond conventional addiction treatment. Emerging data indicate that these may improve retention and outcomes. Comprehensive treatment is becoming a broader concept than ever before. Methodology is emerging to rate and rank treatment program quality and to more precisely target programs' needs for improvement. Attendees will discuss issues in translating these interventions, their research findings, and how they address treatment in the era of healthcare reform.

    David Gastfriend

    MD, DFASAM

    David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.

    Adam C. Brooks

    PhD

    Adam Brooks, PhD, is the Senior Vice President of Research at the Treatment Research Institute (TRI). Dr. Brooks has a Ph.D. in clinical psychology with a specialization in marital and family therapy from St. John's University. Prior to joining TRI, he was at the Columbia University Division on Substance Abuse where he treated substance abusing patients using a variety of empirically validated treatments. His research is focused on the study of behavioral psychosocial treatment for use in community based substance abuse treatment in specialty care and integrated settings, and the development of technologies to facilitate these efforts. He is an expert supervisor in Motivational Interviewing, and has extensive experience training and supervising community clinicians in Empirically Supported Treatments (ESTs). Since joining TRI, Dr. Brooks has conducted research on computer-assisted treatment and training interventions, use of phone technology in treatment and recovery monitoring, workforce development in the use of evidence-based practices and the creation of and testing of tools to support these practices. Dr. Brooks has significant experience working with patient and community stakeholders, having worked with patient and counselor focus groups and community advisory boards on multiple current and past projects. He is currently studying the use of a specialized community disease management to reduce substance use and hospital readmissions, and developing and testing a patient-centered multimedia curriculum that will uses a shared decision making approach to introduce patients to early recovery content including the role of Medication Assisted Treatment (MAT) in recovery.

    Mady Chalk

    PhD, MSW

    Mady Chalk, Ph.D., MSW, Senior Policy Advisor, Treatment Research Institute and Principal and Managing Director, The Chalk Group

    Public policy researcher, clinician, and academician with over 30 years of experience demonstrating strong leadership, management, and organizational development skills in fields of mental and substance use disorders treatment and research. Principal and Managing Director of The Chalk Group which provides customized consulting services to public and private purchasers and to national associations on health care, substance use and mental health treatment, policy and systems development; assists purchasers and national associations in strategic planning for substance use and mental health policy initiatives in a healthcare reform environment and implementation of high quality best practices within a framework of accountability for performance. As Senior Piolicy Advisor to the Treatment Research Institute, collaborates with Oregon Health Sciences University on a NIDA-funded grant to study methods to improve the use of FDA-approved medications in the treament of addictions in a commercial health plan; provide consultation services to the CMS Innovator Accelerator Program for Substance Use Disorders, working with Medicaid agencies and others in State governments across the United States. Provide leadership to the Washington Circle on issues related to performance measurement for subtance use diorders. Adjunct Faculty at Uniformed Services University of the Health Sciences.

    Kathleen Meyers

    PhD

    Senior Research Scientist

    Treatment Research Institute

    David Festinger

    PhD

    David S. Festinger, Ph.D. is a Senior Scientist in TRI's Section on Law and Ethics Research and a Professor and Director of Substance Use Research and Training at the Philadelphia College of Osteopathic Medicine's Department of Psychology. Dr. Festinger holds a Ph.D. in clinical psychology, Masters Degrees in both counseling and clinical health psychology, and is a licensed clinical psychologist. He is the President Elect of American Psychological Association Division 28 on Psychopharmacology and Substance Abuse. Dr. Festinger's research has focused primarily on empirically isolating the active mechanisms of drug courts, developing empirically based dispositional procedures for substance abusing offenders, and bringing experimental research methods to bear on major ethical questions facing research participants in substance abuse research. His research has resulted in a number of statistically and clinically significant findings including reductions in drug use and criminal recidivism and improved psychosocial functioning among drug abusers. In addition, this research has informed the development of important clinical tools including the Treatment Research Institute-Court Evaluation Program (TRI-CEP™) and the Risk and Needs Triage (RANT®). Dr. Festinger has served as Principal Investigator and Co-Principal Investigator on numerous grants from the National Institute of Drug Abuse and has authored numerous articles and chapters.

  • Prescribe to Prevent Overdose: Naloxone Rescue Kits for Patients and Families (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Expanding the use of naloxone in the community to reduce overdoses is one of the Department of Health and Human Services three priorities in responding to the opioid epidemic. This workshop will provide attendees with the knowledge and skills they need to incorporate overdose prevention education and naloxone rescue kits into their addiction medicine practices and expand its access in their communities.

    Expanding the use of naloxone in the community to reduce overdoses is one of the Department of Health and Human Services three priorities in responding to the opioid epidemic. This workshop will provide attendees with the knowledge and skills they need to incorporate overdose prevention education and naloxone rescue kits into their addiction medicine practices and expand its access in their communities. Presenters include a physician prescriber, an expert in pharmacy naloxone distribution, and a public health lawyer, each of whom has supported the development of several naloxone rescue kit programs in several venues. The session includes videos of patient-pharmacist-prescriber encounters that model how to provide a patient overdose education and a naloxone rescue kit. The session also includes 2-minute instructional videos for the available naloxone rescue kit formulations designed for you to use with your patients. Using didactic content, video vignettes, and an interactive practice implementation session, this 90-minute workshop will review the epidemiology of overdose and rationale for distributing naloxone rescue kits to opioid users and their social networks, describe current implementation models, discuss how to incorporate overdose prevention into one's practice and explain the legal and policy environment for naloxone rescue kit distribution. Developed with funding from the Substance Abuse Mental Health Services Administration, this program is a companion to the website www.prescribetoprevent.org, which includes resources to help health care providers educate their patients to reduce overdose risk and provide naloxone rescue kits to patients and their social networks. This presentation will build on this team's 2015 ASAM overdose prevention workshop and include a discussion of evaluation feedback and frequently asked questions received through the online learning module.

    Alexander Y. Walley

    MD, MSc, FASAM

    Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. 

    Corey Davis

    JD, MSPH

    N/A

    Traci Green

    PhD, MSc

    Dr. Green is Deputy Director of the Boston Medical Center Injury Prevention Center and Associate Professor of Emergency Medicine and Epidemiology at the Warren Alpert School of Medicine at Brown University. She is an epidemiologist whose research focuses on drug abuse, addiction, and injury. She earned a Master of Science in Epidemiology and Biostatistics from McGill University and a PhD in Epidemiology from Yale University. She helped design the ASI-MV®, a real-time illicit and prescription drug abuse surveillance system developed by Inflexxion, Inc. Dr. Green helped co-found www.prescribetoprevent.org, chairs the Drug Overdose Prevention and Rescue Coalition for the Rhode Island Department of Health, and serves as an advisor to the Rhode Island Governor on addiction and overdose. Her research is supported by the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, the Agency for Healthcare Research and Quality, the Patient Centered Outcomes Research Institute, and the Department of Justice.

  • Complex Addiction Medicine Clinical Cases Discussion (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 credits while learning about four complex addiction medicine cases. The cases involve: 1. Buprenorphine tapering 2. Pain and addiction and Opioids management 3. Management of methadone induced long QTc interval in a symtomatic hospitalized methadone maintained patient 4. Stepwise approach to alcohol relapse prevention pharmacotherapy, utilizing both FDA and non-FDA approved medications. Each case will be presented and then interactive discussion encouraged on appropriate management. Evidence-based literature, where applicable will be discussed.

    Four real cases, with outcome data will be presented. The cases deal with: 1. Decision to taper buprenorphine. When a patient desires to taper off and withdraw from buprenorphine maintenance what are the considerations which need to be discussed with the patient? 2. Pain management in the setting of an opioid use disorder--using both methadone and buprenorphine. Patients with an opioid use disorder present unique pain management issues. Can methadone be used for pain management in the setting of an opioid use disorder? Is transferring to buprenorphine a logical goal? 3. Methadone induced symptomatic prolonged QTc interval management. Methadone may prolong the QTc interval. If a patient is symptomatic with syncope and Torsades D'Pointe arrythmia, what should be done? ' 4. Alcohol Relapse prevention pharmacotherapy, utilizing both FDA approved and off label medications. There are 3 FDA approved pharmacotherapies for prevention of relapse in alcohol use disorder. There are non FDA approved medications, such as gabapentin and topirimate, which have evidence of efficacy. A stepwise approach to pharmacotherapy in a patient will be discussed. Each case will be presented, discussion on management encouraged, and final outcomes discussed.


    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician at Mount Sinai Beth Israel, Department of Psychiatry and Behavioral Sciences, since 1983, and is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.  He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.  Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease.  He  lectures frequently and has been published on a variety of addiction medicine topics.

    Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT and PCSS-O mentoring programs. He has co-chaired  the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art Course and  is a reviewer for the Journal of Addiction Medicine. Currently Dr. Salsitz is the chair of the ASAM REMS ER/LA Opioids committee. Dr. Salsitz is a member of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He is the recipient of the 2014 ASAM Annual Award. Dr. Salsitz is a member of the Medical Advisory Panel, for the New York State Office of Alcohol and Substance Abuse Services.

    R. Jeffrey Goldsmith

    MD, DLFAPA, DFASAM

    Dr. Goldsmith began his addiction medicine career in 1974 as a medical student, learning about the disease of alcoholism as a counselor for one of the Department of Transportation's Alcohol Safety Action Projects. He received his medical training at the University of Cincinnati College of Medicine from 1973-1977 and finished his residency in Psychiatry at UC in 1981.

    Recent Employment history

    In 1994 Dr. Goldsmith joined the VA fulltime. From 1994-2009, he split his time between Dual Diagnosis Services and other duties including all of the psychiatric consultations for the hospital (1994-1997) and research with the Clinical Trials Network (1995-2009). He was an active member of Cincinnati's NIDA research group, and Cincinnati's principal investigator for its pivotal study of buprenorphine/naloxone for opiate addiction. Dr Goldsmith also created an integrated Primary Care Mental Health program with the director of Primary Care, initiated in 2007 and still active.

    Currently Dr. Goldsmith works in the VA Buprenorphine Treatment Clinic.

    Teaching

    In 1994, Dr. Goldsmith developed an ACGME accredited Addiction Psychiatry Fellowship and the following year was funded by the Dept. of Veterans Affairs for a two year Addiction Medicine Fellowship. He holds the title of Professor of Clinical Psychiatry in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati. He was addiction fellowship director from 1989 to 2007 and continues to teach in addiction fellowships: Psychiatry and ABAM.

    ASAM involvement

    Dr. Goldsmith joined ASAM in 1984, became ASAM certified in 1986 and got his CAQ in Addiction Psychiatry in 1994. He has been on the CME committee since then, and was its chair for nine years from 2000-2009. Dr Goldsmith is President of ASAM 2015-2017.

Annual Conference Presenters

Name

Disclosure Information

Anthony J. Accurso, MD

Nothing to Disclose

Arpana Agrawal, PhD

Nothing to Disclose

Barbara Andraka-Christou, JD

Nothing to Disclose

Elie Aoun, MD

Nothing to Disclose

Soraya Asadi, MD, DABAM

Nothing to Disclose

Genie L. Bailey, MD

Nothing to Disclose

Joshua Barclay, MD, MS, MSHR, FACP

Nothing to Disclose

Gabriela Barnett, MA

Nothing to Disclose

Gavin Bart, MD PhD FASAM FACP

Nothing to Disclose

Kaitlan Baston, MD

Nothing to Disclose

Lou Baxter, MD, FASAM

Nothing to Disclose

Inna Belfer, MD, PhD

Nothing to Disclose

Lia Bennett, MPH

Nothing to Disclose

Michael F Bierer, MD MPH

Nothing to Disclose

Adam Bisaga, MD

Alkermes, Inc (Self) : Other Financial or Material Support (Status: Ongoing), received research suport (Status: Ongoing)

Richard D. Blondell, MD

Nothing to Disclose

Katharine Bradley, MD MPH

Nothing to Disclose

Adam C. Brooks, PhD

Nothing to Disclose

E Marshall Brooks, PhD

Nothing to Disclose

Lawrence S. Brown, MD, MPH, FASM

CDC Foundation: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Randall Brown, MD, PhD, FASAM

Nothing to Disclose

Richard Brown, MD, MPH

Wellsys, LLC: Ownership Interest includes stock, stock options, patent or other intellectual property

Greg Bunt, MD

Nothing to Disclose

Rachael Burgower, MA

Nothing to Disclose

Ryan Caldeiro, MD

Nothing to Disclose

Melinda Campopiano, MD

Nothing to Disclose

Katherine V. Carroll, PA-C

Nothing to Disclose

Mady Chalk, PhD, MSW

Nothing to Disclose

Yuchiao Chang, PhD

Nothing to Disclose

Faye Chao, MD

Nothing to Disclose

Margaret S. Chisolm, MD

Nothing to Disclose

Veronic Clair, MD, MSc, CCFP, FRCPC, PhD

Nothing to Disclose

H. Westley Clark, MD, JD, MPH, FASAM

Nothing to Disclose

Kelly Clark, MD, MBA, FASAM

Nothing to Disclose

Diana Coffa, MD

Nothing to Disclose

Stephen Colameco, MD, MEd, FASAM

Nothing to Disclose

Sophie Collins, MD

Nothing to Disclose

Wilson M. Compton, MD, MPE

3M Corp.: Ownership Interest includes stock, stock options, patent or other intellectual property

General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property

Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property

Micah T. Conti, BA

Nothing to Disclose

Roxanne Cook, RN

Nothing to Disclose

Desiree A Crevecoeur-MacPhail, PhD

Nothing to Disclose

Andrew A. Danzo,

Nothing to Disclose

Smita Das, MD

Nothing to Disclose

Amy Davis, DO, MS, FACP, FAAHPM

Nothing to Disclose

Corey Davis, JD, MSPH

Nothing to Disclose

Michael A. Dekker, DO

Nothing to Disclose

Caroline M. DuPont, MD

Nothing to Disclose

Paul H. Earley, MD, DFASAM

Alkermes, Inc.: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Earley COnsulatncy, LLC: Employment

Georgia Professionals Health Program: Employment

RiverMend Health : Consultant/Advisory Board

Ryan Eisenacher,

Nothing to Disclose

Sheri Eisert, PhD

Nothing to Disclose

Honora Englander, MD

Nothing to Disclose

David H. Epstein, PhD

Nothing to Disclose

Igor Epstein, DO

Nothing to Disclose

Anthony Estreet, PhD

Nothing to Disclose

Oluwaseun Falade, MD

Nothing to Disclose

Patrick Fehling, MD

Nothing to Disclose

David Festinger, PhD

Nothing to Disclose

David A. Fiellin, MD

Pinney Associates: Consultant/Advisory Board

Michael Fingerhood, MD

Nothing to Disclose

Marc Fishman, MD, FASAM

Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Jessica N. Flori, BA

Nothing to Disclose

Thomas E. Freese, PhD

Nothing to Disclose

John Fromson, MD

Nothing to Disclose

Jessie Gaeta, MD

Nothing to Disclose

Marc Galanter, MD

Nothing to Disclose

Eliot L. Gardner, PhD

Nothing to Disclose

David R. Gastfriend, MD

Nothing to Disclose

Shareh Ghani, MD

Nothing to Disclose

Udi Ghitza, PhD

Nothing to Disclose

David Goldman, MD

Nothing to Disclose

R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

Center for Health & Innovation Learning (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Hazelden Betty Ford Foundation (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

David A. Gorelick, MD, PhD, DLFAPA

Nothing to Disclose

Kevin Gray, MD

Nothing to Disclose

William Greaves, MD, MSPH

Nothing to Disclose

Traci Green, PhD, MSc

Nothing to Disclose

Mark K. Greenwald, PhD

Indivior: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Jessica Gregg, MD, PhD

Nothing to Disclose

Allison F. Hall, BS

Nothing to Disclose

Susan Hayashi, PhD

Nothing to Disclose

Gary Henschen, MD LFAPA

Nothing to Disclose

Sara K. Hertzel, BA

Nothing to Disclose

Marilyn A. Huestis, PhD

Nothing to Disclose

Andrew Huff, LPC

Nothing to Disclose

Brian Hurley, MD, MBA

Nothing to Disclose

Polly Ingram, BA

Nothing to Disclose

Krystyna R. Isaacs, PhD

Nothing to Disclose

J Harry Isaacson, MD

Nothing to Disclose

Benjamin D. Johnson, DO

Nothing to Disclose

Matthew W. Johnson, PhD

Nothing to Disclose

Hendree E. Jones, PhD

Nothing to Disclose

Jolene Joseph, LISW

Nothing to Disclose

Alene Kennedy-Hendricks, PhD

Nothing to Disclose

Jag H. Khalsa, MS, PhD

Nothing to Disclose

Sonnie Kim, PharmD

Braeburn Pharmaceuticals: Employment

Kaylin Klie, MD

Nothing to Disclose

Andrea Kline-Simon, MS

Nothing to Disclose

George Kolodner, MD

Nothing to Disclose

Philip Todd. Korthuis, MD, MPH

Nothing to Disclose

Henry R. Kranzler, MD

Alkermes: Consultant/Advisory Board

Lundbeck Pharmaceuticals: Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Member of Amer Soc Clin Psychopharmacology's Alcohol Clinical Trials Initiative, supported by Alkermes, Lilly, Lundbeck, AbbVie, and Ethypharm : Consultant/Advisory Board

Otsuka Pharmaceuticals: Consultant/Advisory Board

Mark l. Kraus, MDDFASAM

Nothing to Disclose

Kevin Kunz, MD

Nothing to Disclose

JoAn Laes, MD

Nothing to Disclose

Shenghan Lai, MD, MPH

Nothing to Disclose

Bernard Le Foll, MD, PhD, MCFP

Bioprojet: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

GW pharma: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support

Mettrum: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Pfizer: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Joshua D. Lee, MD, MSc

Alkermes, Inc: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Anne Leopold, MSc

Nothing to Disclose

Petros Levounis, MD, MA

Nothing to Disclose

Chris Lewis, MA

Nothing to Disclose

Thomas Lincoln, MD

Nothing to Disclose

Raye Z. Litten, PhD

Nothing to Disclose

Michelle Lofwall, MD

Braeburn: Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

CVS Caremark: Consultant/Advisory Board

Orexo: Consultant/Advisory Board

PCM Scientific: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

David Lott, MD, FAPA, FASAM

Nothing to Disclose

Peter Luongo, PhD

Nothing to Disclose

Lauren MacAfee, MD

Nothing to Disclose

Jose R. Maldonado, MD, FAPM, FACFE

Nothing to Disclose

Herbert L Malinoff, MD, FACP, DFASAM

Nothing to Disclose

Ajay Manhapra, MD

Nothing to Disclose

Alex Manini, MD, MS

Nothing to Disclose

David Marcovitz, MD

Nothing to Disclose

Laura Martin, MD

Nothing to Disclose

Steven C. Matson, MD

Nothing to Disclose

Alexis K Matusiewicz, PhD

Nothing to Disclose

David Mee-Lee, MD

Nothing to Disclose

Kathleen Meyers, PhD

Nothing to Disclose

Jennifer Michaels, MD

Nothing to Disclose

David Miller, MD

Nothing to Disclose

William R Miller, PhD

Guilford Press (Self) : Royalties (Status: Ongoing)

Ivan Montoya, MD, MPH

Nothing to Disclose

Landhing M. Moran, PhD

Nothing to Disclose

Dan Morhaim, MD

Nothing to Disclose

Warren Morris, MD FASAM

Nothing to Disclose

Howard B. Moss, MD

Nothing to Disclose

Sam Muszynski, JD

Nothing to Disclose

Lewis Nelson, MD

Nothing to Disclose

Doug Nemecek, MD, MBA

Nothing to Disclose

Edward Nunes, MD

Nothing to Disclose

Patrick O'Connor, MD, MPH, FACP

Nothing to Disclose

Yngvild Olsen, MD, MPH

Nothing to Disclose

Nicholas A. Pace, MD

Nothing to Disclose

Patricia Pade, MD

Nothing to Disclose

Stephen Patrick, MD, MPH, MS

Vermont Oxford Network (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/2015)

Joseph Perpich, MD, JD

Nothing to Disclose

Heather Peterson, PA-C

Nothing to Disclose

Karran Phillips, MD, MSc

Nothing to Disclose

Mel Pohl, MD, FASAM

Las Vegas Recovery Center: Employment

Cara Poland, MD, MEd

Nothing to Disclose

Sabrina Poole, PsyD

Nothing to Disclose

Lantie Quinones, MD

Nothing to Disclose

Darius Rastegar, MD

Nothing to Disclose

James Ray, PharmD

Alchemy Consulting, P.C.: Ownership Interest includes stock, stock options, patent or other intellectual property

Michael D Reisman, JD

Nothing to Disclose

Traci Rieckmann, PhD

Nothing to Disclose

Richard K. Ries, MD

Nothing to Disclose

Megan M. Risi, BS

Nothing to Disclose

Deidra Y Roach, MD

Nothing to Disclose

Maureen Roberts, MD

Nothing to Disclose

Sarah CM. Roberts, DrPH

Nothing to Disclose

Naoko A. Ronquest, PhD

Nothing to Disclose

Robert Roose, MD, MPH, FASAM

Nothing to Disclose

Richard N. Rosenthal, MD

Braeburn Pharmaceticals: Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Alphonse Ken Roy, MD, FASAM, DLFAPA

Nothing to Disclose

Payel Roy, MD

Nothing to Disclose

Gregory Rudolf, MD, FASAM

Nothing to Disclose

Beth A. Rutkowski, MPH

Nothing to Disclose

Kelley Saia, MD,

Nothing to Disclose

Richard Saitz, MD, MPH, FASAM

Nothing to Disclose

Edwin A. Salsitz, MD, DFASAM

Nothing to Disclose

Ruchi Sanghani, MA

Nothing to Disclose

Rebekah Savage, MD, MPH

Nothing to Disclose

Zev Schuman-Olivier, MD

Nothing to Disclose

Robert Schwartz, MD

Reckitt Benckiser: Consultant/Advisory Board

Daniel A. Schwarz, MD, CMRO

Nothing to Disclose

Peter Selby, MBBS, FCFP, dipABAM

Bristol Meyer Squibb: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Johnson and Johnson: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support

Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Nadav Shalit, MD

Nothing to Disclose

Randi G. Sokol, MD, MPH, MMedEd

Nothing to Disclose

Robert Sokol, MD

Nothing to Disclose

Rachel Solotarof, MD, MCR

Nothing to Disclose

Christopher Stauffer, MD

Nothing to Disclose

Robert Sterling, PhD

Nothing to Disclose

Kenneth Stoller, MD

Nothing to Disclose

Geetha Subramaniam, MD, DFAPA

Nothing to Disclose

Angela Suen, BS

Nothing to Disclose

Brian Suffoletto, MD, MS

healthStratica (Self) : Royalties (Status: Ongoing)

Fatimah Tahil, MD, MPH, DFAPA, FAPM

Nothing to Disclose

John Teal, MD

Nothing to Disclose

Mishka Terplan, MD, MPH, FACOG, FASAM

Nothing to Disclose

Sebastian T. Tong, MD, MPH

Nothing to Disclose

Paul A. Trowbridge, MD, MPH

Nothing to Disclose

Allison Verbyla, MPH Candidate

Nothing to Disclose

Annmarie Lyn. Vilkins, DO, MSc

Nothing to Disclose

Hoa Vo, PhD

Nothing to Disclose

Frank Vocci, PhD

Braeburn Pharmaceuticals: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Demerx: Consultant/Advisory Board

Pinney Associates: Consultant/Advisory

Reckitt-Benckiser Pharmaceuticals: Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Nora D Volkow, MD

Nothing to Disclose

Sarah E. Wakeman, MD

Nothing to Disclose

Alexander Y. Walley, MD, MSc

Nothing to Disclose

James Walsh, MD

Nothing to Disclose

Vickie Walters, LCSW-C

Nothing to Disclose

Mark Ware, BA, MBBS, MRCP(UK), MSc

Canadian Consortium for the Investigation of Cannabinoids : Employment

CanniMed: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Damien Christopher Warsavage, YE-CRS, CRS

Nothing to Disclose

Michael F. Weaver, MD, FASAM

Nothing to Disclose

Melissa Weimer, DO, MCR

Nothing to Disclose

Mark A Weiner, MD, DFASAM

Nothing to Disclose

Constance Weisner, DrPH, LCSW

Nothing to Disclose

Leana Wen, MD, MSc

Nothing to Disclose

Joseph Westermeyer, MD, PhD, MPH

Nothing to Disclose

Timothy Wiegand, MD, DABAM, FACMT, FAACT

Nothing to Disclose

Bonnie b. Wilford, MS

Nothing to Disclose

Jeffrey Wilkins, MD, FASAM, DFAPA

Nothing to Disclose

Justin Wolfe, MSW, LCSW, CADC

Nothing to Disclose

Li-Tzy Wu, ScD RN MA

Nothing to Disclose

Martha J. Wunsch, MD FAAP FASAM

Nothing to Disclose

Stephen Wyatt, DO

Nothing to Disclose

Annual Conference Planning Committee

Name

Disclosure Information

Anthony Paul Albanese, MD, DFASAM

Gilead Sciences: speaker/ad board, honorarium; AbbVie Pharmaceuticals: speaker/ad board, honorarium; Merck Pharmaceuticals: speaker/ad board, honorarium; Genentech Pharmaceuticals: speaker/ad board, honorarium

Gavin Bart, MD, PhD, FASAM, FACP

Nothing to Disclose

Susan Kaye Blank, MD, DFASAM

Nothing to Disclose

Michael A. Dekker, DO

Nothing to Disclose

Christina M. Delos Reyes, MD, FASAM

Nothing to Disclose

Michael Fingerhood, MD, FACP

Nothing to Disclose

Peter David Friedmann, MD, MPH, FACP, DFASAM

Alkermes: In-Kind Support, Research; Orexo: Honoraria, Facilitated roundtable; Indivior: Honoraria, Advisory Board

Adam J. Gordon, MD, MPH, FACP, CMRO, DFASAM

Nothing to Disclose

Joshua D. Lee, MD MSc

Does Disclose

Michelle Lofwall, MD, DFASAM

Does Disclose

Joseph Montgomery Matta, MD, FASAM

Nothing to Disclose

Mark P. Schwartz, MD, FASAM

Nothing to Disclose

Sarah E. Wakeman, MD

Nothing to Disclose

Mark A. Weiner, MD, DFASAM

Nothing to Disclose

Norman Wetterau, MD, FAAFP, DFASAM

Nothing to Disclose

CME Committee

Name

Disclosure Information

Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair, Reviewer

Nothing to Disclose

Catherine Friedman, MD

Vice Chair

Nothing to Disclose

Noel Ilogu, MD, MRCP

Nothing to Disclose

Hebert L. Malinoff, MD, FACP, FASAM

Nothing to Disclose

Edwin A. Salsitz, MD, FASAM, Reviewer

Nothing to Disclose

John C. Tanner, DO, FASAM, CCFC, MRO

Reckitt-Benckiser: Honorarium, Speaker; Orexo: Honorarium, Speaker; BDSI: Honorarium, Speaker & Consultant

Learning Objectives

At the conclusion of the conference, participants should be able to:

  • Employ current and new clinical approaches to treatment in a variety of settings.
  • Utilize and promote evidence-based approaches for clinical treatment of substance abuse disorders.
  • Recognize issues that arise when treating individuals in diverse and special populations or with special physical, health and mental illnesses.
  • Identify, diagnose, and treat substance use disorders in clinical populations.
  • Describe the development of new science and treatments in addiction medicine.

Accreditation Council for Continuing Medical Education

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASAM has designated this enduring material for a maximum of 69 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABAM Maintenance of Certification Program (MOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 69 AMA PRA Category 1 Credits for completing the ASAM 47th Annual Conference and Pre-Courses.

Who should attend:
  • Physicians and Clinicians
  • Researchers and Academics
  • Counselors and Students
  • Other Health Care Professionals

Dedicated to increasing access and improving the quality of addiction treatment and care.